NANT Homepage
NANT Homepage About Us How You Can Help NANT Trials Contact Us Search the Site

Menu

Publications

Publications from studies of the NANT consortium as well as from research of investigators in the NCI Program Project "Biology and Therapy of High-Risk Neuroblastoma" are available for download from this site.

Please select from the drop-down menu below to view the list of available downloads for that year. Downloadable articles are linked in green. Please click or right-click and choose "Save As" to download them. Articles which are not yet available are not linked.

Publications are arranged in chronological order and alphabetically by last name.

Publications from 2000

  1. PDF icon  Anderson, C. P., Keshelava, N., Satake, N., Meek, W. H., and Reynolds, C. P.
    Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression. Med.Pediatr.Oncol., 35: 659-662, 2000.
  2. PDF icon  Keshelava, N., Zuo, J. J., Waidyaratne, N. S., Triche, T. J., and Reynolds, C. P.
    p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med.Pediatr.Oncol., 35: 563-568, 2000.
  3. PDF icon  Keshelava, N., Groshen, S., and Reynolds, C. P.
    Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother.Pharmacol., 45: 1-8, 2000.
  4. PDF icon  Matthay, K. K. and Reynolds, C. P.
    Is there a role for retinoids to treat minimal residual disease in neuroblastoma? Br.J.Cancer, 83:1121-1123, 2000.
  5. PDF icon  Maurer, B. J., Melton, L., Billups, C., Cabot, M. C., and Reynolds, C. P.
    Synergistic cytotoxicity in solid tumor cell lines between N-(4- hydroxyphenyl)retinamide and modulators of ceramide metabolism. J.Natl.Cancer Inst., 92: 1897-1909, 2000.
  6. PDF icon  Reynolds, C. P. and Seeger, R. C.
    Neuroblastoma. In C. M. Haskell (ed.), Cancer Treatment, Fifth ed, pp. 1214-1236. Philadelphia: W.B. Saunders, 2000.
  7. PDF icon  Seeger, R. C., Reynolds, C. P., Gallego, R., Stram, D. O., Gerbing, R. B., and Matthay, K. K.
    Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J.Clin.Oncol, 18: 4067-4076, 2000.

Publications from 2001

  1. PDF icon  Anderson, C. P., Seeger, R. C., Satake, N., Monforte-Munoz, H. L., Keshelava, N., Bailey, H.H., and Reynolds, C. P.
    Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J.Pediatr.Hematol.Oncol., 23: 500-505, 2001.
  2. PDF icon  Keshelava, N., Zuo, J. J., Chen, P., Waidyaratne, S. N., Luna, M. C., Gomer, C. J., Triche, T. J., and Reynolds, C. P.
    Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res, 61:6185-6193, 2001.
  3. PDF icon  Metelitsa, L. S., Naidenko, O. V., Kant, A., Wu, H. W., Loza, M. J., Perussia, B., Kronenberg, M., and Seeger, R. C.
    Human NKT Cells Mediate Antitumor Cytotoxicity Directly by Recognizing Target Cell CD1d with Bound Ligand or Indirectly by Producing IL-2 to Activate NK Cells. J.Immunol., 167: 3114-3122, 2001.
  4. Reynolds, C. P. and Lemmons, R. S.
    Retinoid therapy of childhood cancer. Hematol.Oncol Clin.North Am., 15: 867-910, 2001.
  5. PDF icon  Reynolds, C. P. and Seeger, R. C.
    Detection of Minimal Residual Disease in Bone Marrow During or After Therapy as a Prognostic Marker for High-Risk Neuroblastoma. Am.J.Pediatr.Hematol.Oncol., 23: 150-152, 2001.
  6. PDF icon  Tang, H. R., Da Silva, A. J., Matthay, K. K., Price, D. C., Huberty, J. P., Hawkins, R. A., and Hasegawa, B. H.
    Neuroblastoma imaging using a combined CT scanner-scintillation camera and 131I-MIBG. J.Nucl.Med., 42: 237-247, 2001.
  7. PDF icon  Wang, H., Maurer, B. J., Reynolds, C. P., and Cabot, M. C.
    N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res, 61: 5102-5105, 2001.

Publications from 2002

  1. PDF icon  Anderson, C. P. and Reynolds, C. P.
    Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant., 30:135-140, 2002.
  2. PDF icon  Erdreich-Epstein, A., Tran, L.B., Bowman, N. N., Wang, H., Cabot, M.C., Durden, D.L., Vlckova, J., Reynolds, C. P., Stins, M.F., Groshen, S., Millard, M.
    Ceramide Signaling in Fenretinide-induced Endothelial Cell Apoptosis. The Journal of Biological Chemistry, 277:49531-49537, 2002.
  3. PDF icon  Ho R. Eggert A. Hishiki T. Minturn JE. Ikegaki N. Foster P. Camoratto AM. Evans AE. Brodeur GM.
    Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Research. 62:6462-6, 2002
  4. PDF icon  Houghton, P.J., Adamson, P.C., Blaney, S., Fine, H.A., Gorlick, R., Haber, M., Helman, L., Hirschfeld, S., Hollingshead, M.G., Israel, M.A., Lock, R.B., Maris, J.M., Merlino, G., Patterson, W., Reynolds, C.P., Shannon, K., Yu, A., Yu, J., Smith, M.A.
    Testing of New Agents in Childhood Cancer Preclinical Models: Meeting Summary, Clinical Cancer Research, 8:3646-3657, 2002.
  5. Wigginton J.M., Wiltrout R.H.
    IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Expert Opinion on Biological Therapy. 2:513-24, 2002.
  6. PDF icon  Yanik, G. A., Levine, J. E., Matthay, K. K., Sisson, J. C., Shulkin, B. L., Shapiro, B., Hubers, D., Spalding, S., Braun, T., Ferrara, J. L., and Hutchinson, R. J.
    Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J.Clin.Oncol, 20: 2142-2149, 2002.

Publications from 2003

  1. PDF icon  Haas-Kogan, D.A., Swift, P.S., Selch, M., Haase, G.M., Seeger, R.C., Gerbing, R.B., Stram, D.O., Matthay, K.K.
    Impact of Radiotherapy for High-Risk Neuroblastoma: A Children's Cancer Group Study. Int. J. Radiation Oncology Biol. Phys., 56: 28-39, 2003
  2. PDF icon  Jaboin J. Hong A. Kim CJ. Thiele CJ.
    Cisplatin-induced cytotoxicity is blocked by brain-derived neurotrophic factor activation of TrkB signal transduction path in neuroblastoma. Cancer Letters. 193:109-14, 2003.
  3. PDF icon  Keshelava, N., Tsao-Wei, D., Reynolds, C. P.
    Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p53. Clinical Cancer Research, 9:3492-3502, 2003.
  4. PDF icon  Matthay, K.K., Edeline, V., Lumbroso, J., Tanguy, M.L., Asselain, B. Zucker, J.M., Valteau-Couanet, D., Hartmann, O., Michon, J.
    Correlation of Early Metastatic Response by 123I-Metaiodobenzylguanidine Scintigraphy With Overall Response and Event-Free Survival in Stage IV Neuroblastoma. Journal of Clinical Oncology, 21: 2486-2491, 2003.
  5. PDF icon  Reynolds, C. P., Matthay, K. K., Villablanca, J. G., Maurer, B. J.
    Retinoid Therapy of High-Risk Neuroblastoma. Cancer Letters, 197:185-192, 2003.
  6. PDF icon  Sohara, Y., Shimada, H., Scadeng, M., Pollack, H., Yamada, S., Ye, W., Reynolds, C. P., and DeClerck, Y. A.
    Lytic Bone Lesions in Human Neuroblastoma Xenograft Involve Osteoclast Recruitment and Are Inhibited by Bisphosphonate. Cancer Research 63:3026-3031, 2003.
  7. PDF icon  Weiss, B., Vora, A., Matthay, K.K., Huberty, J., Hawkins, R.A.
    Secondary Myelodysplastic Syndrome and Leukemia Following 131I-Metaiodobenzylguanidine Therapy for Relapsed Neuroblastoma. Journal of Pediatric Hematology/Oncology, 25: 2003.
  8. PDF icon  Yang, B., Keshelava, N., Anderson, C.P. and Reynolds, C.P.
    Antagonism of Buthionine Sulfoximine Cytotoxicity for Human Neuroblastoma Cell Lines by Hypoxia Is Reversed by the Bioreductive Agent Tirapazamine. Cancer Research 63:1520-1526, 2003

Publications from 2004

  1. PDF icon  Adkins, E. S., Sawin, R., Gerbing, R. B., London, W. B., Matthay, K. K., and Haase, G. M.
    Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. J.Pediatr.Surg., 39: 931-936, 2004.
  2. PDF icon  Batra, S., Reynolds, C. P., and Maurer, B. J.
    Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res., 64: 5415-5424, 2004.
  3. PDF icon  DuBois, S. G., Messina, J., Maris, J. M., Huberty, J., Glidden, D. V., Veatch, J., Charron, M., Hawkins, R., and Matthay, K. K.
    Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J.Clin.Oncol., 22: 2452-2460, 2004.
  4. Goldsby, R. E. and Matthay, K. K.
    Neuroblastoma : evolving therapies for a disease with many faces. Paediatr.Drugs, 6: 107-122, 2004.
  5. PDF icon  Hickeson, M. P., Charron, M., Maris, J. M., Brophy, P., Kang, T. I., Zhuang, H., Khan, J., and Nevrotski, T.
    Biodistribution of post-therapeutic versus diagnostic (131)I-MIBG scans in children with neuroblastoma. Pediatr.Blood Cancer, 42: 268-274, 2004.
  6. PDF icon  Reynolds, C. P., Maurer, B. J., and Kolesnick, R. N.
    Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett., 206: 169-180, 2004.
  7. Reynolds, C. P.
    Detection and treatment of minimal residual disease in high-risk neuroblastoma. Pediatr.Transplant., 8: 56-66, 2004.
  8. PDF icon  Vratilova, J., Frgala, T., Maurer, B. J., and Reynolds, C.P.
    Liquid chromatography method for quantifying N-(4-hydroxyphenyl)retinamide and N-(4-methoxyphenyl)retinamide in tissues. J.Chromatogr.B Analyt.Technol.Biomed.Life Sci., 808: 125-130, 2004.
  9. PDF icon  Wagner, L. M., Crews, K. R., Iacono, L. C., Houghton, P. J., Fuller, C. E., McCarville, M. B., Goldsby, R. E., Albritton, K., Stewart, C. F., and Santana, V. M.
    Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin.Cancer Res., 10: 840-848, 2004.

Publications from 2005

  1. PDF icon  Grigoryan, R., Keshelava, N., Anderson, C., and Reynolds, C. P.
    In vitro testing of chemosensitivity in physiological hypoxia. Methods Mol.Med., 110: 87-100, 2005.
  2. PDF icon  Howard, J. P., Maris, J. M., Kersun, L. S., Huberty, J. P., Cheng, S. C., Hawkins, R. A., and Matthay, K. K.
    Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma. Pediatr.Blood Cancer, 44: 232-239, 2005.
  3. PDF icon  Qualman,S.J., Bowen,J., Fitzgibbons,P.L., Cohn,S.L. and Shimada,H.
    Protocol for the examination of specimens from patients with neuroblastoma and related neuroblastic tumors, Arch.Pathol.Lab Med., 129: 874-883, 2005.
  4. PDF icon  Reynolds, C. P., Sun, B. C., DeClerck, Y. A., and Moats, R. A.
    Assessing growth and response to therapy in murine tumor models. Methods Mol.Med., 111: 335-350, 2005.
  5. PDF icon  Reynolds, C. P. and Maurer, B. J.
    Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol.Med., 110: 173-183, 2005.
  6. PDF icon  Shimada,H.
    In situ neuroblastoma: an important concept related to the natural history of neural crest tumors, Pediatr.Dev.Pathol., 8: 305-306, 2005.
  7. PDF icon  Sohara,Y., Shimada,H. and DeClerck,Y.A.
    Mechanisms of bone invasion and metastasis in human neuroblastoma, Cancer Lett., 228: 203-209, 2005.
  8. PDF icon  Sohara, Y., Shimada, H., Minkin, C., Erdreich-Epstein, A., Nolta, J. A., and DeClerck, Y. A.
    Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Res., 65: 1129-1135, 2005.
  9. PDF icon  Wall,S.J., Werner,E., Werb,Z. and DeClerck,Y.A.
    Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen, J.Biol.Chem., 280: 40187-40194, 2005.

Publications from 2006

  1. PDF icon  Judith G. Villablanca, Mark D. Krailo, Matthew M. Ames, Joel M. Reid, Gregory H. Reaman, and C. Patrick Reynolds
    Phase I Trial of Oral Fenretinide in Children With High-Risk Solid Tumors: A Report From the Children's Oncology Group (CCG 09709), J Clin Oncol 24:3423-3430, 2006.
  2. PDF icon  Chantrain,C.F., Henriet,P., Jodele,S., Emonard,H., Feron,O., Courtoy,P.J., DeClerck,Y.A. and Marbaix,E.
    Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases, Eur.J.Cancer, 42: 310-318, 2006.
  3. PDF icon  Grupp S.A., Cohn S.L., Wall D., Reynolds C.P.
    Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: saving for a rainy day, Pediatr. Blood Cancer, 46: 719-722, 2006.
  4. PDF icon  Jodele,S., Blavier,L., Yoon,J.M. and DeClerck,Y.A.
    Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression, Cancer Metastasis Rev., 25: 35-43, 2006.
  5. PDF icon  Matthay,K.K.
    Is liver metastasis in neuroblastoma an indication for treatment reduction?, Pediatr.Blood Cancer, 46: 269-270, 2006.
  6. PDF icon  Matthay,K.K., Tan,J.C., Villablanca,J.G., Yanik,G.A., Veatch,J., Franc,B., Twomey,E., Horn,B., Reynolds,C.P., Groshen,S., Seeger,R.C. and Maris,J.M.
    Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study, J.Clin.Oncol., 24: 500-506, 2006.
  7. PDF icon  Messina,J.A., Cheng,S.C., Franc,B.L., Charron,M., Shulkin,B., To,B., Maris,J.M., Yanik,G., Hawkins,R.A. and Matthay,K.K.
    Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma, Pediatr.Blood Cancer, 2006.
  8. PDF icon  Mouchess,M.L., Sohara,Y., Nelson,M.D., Jr., DeClerck,Y.A. and Moats,R.A.
    Multimodal imaging analysis of tumor progression and bone resorption in a murine cancer model, J.Comput.Assist.Tomogr., 30: 525-534, 2006.
  9. PDF icon  Osenga,K.L., Hank,J.A., Albertini,M.R., Gan,J., Sternberg,A.G., Eickhoff,J., Seeger,R.C., Matthay,K.K., Reynolds,C.P., Twist,C., Krailo,M., Adamson,P.C., Reisfeld,R.A., Gillies,S.D. and Sondel,P.M.
    A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group, Clin.Cancer Res., 12: 1750-1759, 2006.
  10. PDF icon  Sano,H., Bonadio,J., Gerbing,R.B., London,W.B., Matthay,K.K., Lukens,J.N. and Shimada,H.
    International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age, Eur.J.Cancer, 42: 1113-1119, 2006.
  11. PDF icon  Wu,X., Kim,Y., Sun,B.C., Moore,J.D., Shaw,W.A. and Maurer,B.J.
    Liquid chromatography method for quantifying D-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (D-threo-PPMP) in mouse plasma and liver, J.Chromatogr.B Analyt.Technol.Biomed.Life Sci., 837: 44-48, 2006.

Publications from 2007

  1. PDF icon  Frgala T, Kalous O, Proffitt RT, Reynolds CP
    A novel cytotoxicity assay with a 4 log dynamic range that identifies synergistic drug combinations. Molecular Cancer Therapeutics 6:886-897, 2007.
  2. Harned TM, Kalous O, Neuwelt A, Loera J, Ji L, Iovine P, Sposto R, Neuwelt EA, Reynolds CP
    Sodium Thiosulfate (STS) administered six hours after cisplatin does not compromise anti-neuroblastoma activity. Clinical Cancer Research (In Press, 2007).
  3. Keshelava N, Davicioni E, Zesheng Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP
    Inhibition of histone deacetylase (HDAC) 1, a drug target identified by expression profiling, sensitizes multi-drug-resistant neuroblastoma cell lines to cytotoxic agents. J National Cancer Institute (In Press, 2007)
  4. PDF icon  Keshelava N, Davicioni E, Zesheng Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP
    Inhibition of histone deacetylase (HDAC) 1, a drug target identified by expression profiling, sensitizes multi-drug-resistant neuroblastoma cell lines to cytotoxic agents. J National Cancer Institute 99:1107-19, 2007.
  5. PDF icon  Maurer BJ, Kalous O, Yesair DW, Wu X, Vratilova J, Maldonado V, Khankaldyyan V, Frgala T, Sun BC, McKee RT, Burgess SW, Shaw WA, Reynolds CP
    Improved oral delivery of N-(4-hydroxyphenyl)retinamide with novel LYM-X-SORBTM organized lipid complex in mice. Clinical Cancer Research 13:3079-3086, 2007.
  6. PDF icon  Peng H, Sohara Y, Moats RA, Nelson MD Jr, Groshen SG, Ye W, Reynolds CP, DeClerck YA
    The activity of zoledronic acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and ras-mediated tumor cell survival and proliferation. Cancer Research 67:9346-55, 2007.
  7. Song L, Ara T, Wu HW, Woo CW, Reynolds CP, Seeger RC, DeClerck YA, Thiele CJ, Richard Sposto R, Metelitsa LS
    MYCN oncogene negatively regulates localization of Va24-invariant natural killer T cells to the disease site in neuroblastoma. J Clinical Investigation (In Press, 2007)

Publications from 2009

  1. PDF icon  Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM
    Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J.Clin.Oncol. 2009 Mar 1;27 (7):1020-5. PMCID:PMC2738616
  2. PDF icon  Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JR, Maris JM, Hawkins RA, Daldrup-Link HE, Jackson HA, Matthay KK
    Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J.Clin.Oncol. 2009 Mar 10;27(8):1290-6. PMCID:PMC2667827
  3. PDF icon  Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, Jackson HA, Mari AC, Carlson D, Maris J, Hawkins R, Matthay KK
    Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J.Clin.Oncol. 2009 Nov 10;27(32):5343-9. PMCID:PMC2773221

Publications from 2010

  1. PDF icon  Russell HV, Groshen S, Ara T, DeClerck YA, Hawkins R, Jackson JA, Daldrup-Link HE, Marachelian A, Skerjanec A, Park JR, Katzenstein H, Matthay KK, Blaney SM, Villablanca JG
    A phase I study of zoledronic acid and low dose cyclophosphamide in recurrent/refractory neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) study. Pediatric Blood & Cancer, Nov 2010. PMID: 21077182

Publications from 2011

  1. PDF icon  Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, Huberty J, Franc B, Sposto R, Groshen S, Denice Wei D, Fitzgerald P, Maris JM, Yanik G, Hawkins RA, Villablanca JG, Matthay KK
    Thyroid and Hepatic Function After High Dose 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Neuroblastoma. Pediatr Blood Cancer. Feb;56(2):191-201, 2011.PMID: 20830775
  2. PDF icon  Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, Groshen S, Hellriegel ET, Bensen-Kennedy D, Matthay KK, BrodeurGM and Maris JM
    Phase I Trial of Lestaurtinib for Children with Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study. Cancer Chemotherapy and Pharmacology 2011; in press.
  3. PDF icon  Cooper J, Hwang K, Singh H, Wang D, Reynolds CP, Curley R, Williams S, Maurer B, and Kang M
    Fenretinide Metabolism in Humans and Mice: Utilizing Pharmacologic Modulation of its Metabolic Pathway to Increase Systemic Exposure. Submitted, British Journal of Pharmacology, 2011